Elderly patients are hyperresponsive to potent P2Y12 inhibitors

Figures

• 

  Figure 1. Platelet aggregation in aggregation units (AU) by multiple electrode aggregometry in response to (A) arachidonic acid (AA), (B) adenosine diphosphate (ADP), (C) collagen (COL), (D) SFLLRN, and (E) AYPGKF in prasugrel-treated patients <70 years and ≥70 years. The boundaries of the box show the lower and upper quartiles, the line inside the box represents the median. Whiskers are drawn from the edge of the box to the highest and lowest values that are outside the box but within 1.5 times the box length.

• 

  Figure 2. Platelet aggregation in aggregation units (AU) by multiple electrode aggregometry in response to (A) arachidonic acid (AA), (B) adenosine diphosphate (ADP), (C) collagen (COL), (D) SFLLRN, and (E) AYPGKF in ticagrelor-treated patients <70 years and ≥70 years. The boundaries of the box show the lower and upper quartiles, the line inside the box represents the median. Whiskers are drawn from the edge of the box to the highest and lowest values that are outside the box but within 1.5 times the box length.

• 

  Figure 3. Platelet aggregation in aggregation units (AU) by multiple electrode aggregometry in response to adenosine diphosphate (ADP) in patients aged <60 years, 60 to 64 years, 65 to 69 years, and ≥70 years. The boundaries of the box show the lower and upper quartiles, the line inside the box represents the median. Whiskers are drawn from the edge of the box to the highest and lowest values that are outside the box but within 1.5 times the box length.